论文部分内容阅读
研究肝癌组织中是否存在激活T细胞以及如何阻断激活T细胞凋亡,增加激活T细胞寿命对于肝癌的治疗具有重要意义.我们应用免疫组化及原位杂交技术研究20例肝癌组织中肿瘤侵润淋巴细胞(TIL)的穿孔素及Fas-L表达情况,结果表明80%肝部癌组织中存在着表达穿孔素及Fas-L的TIL细胞,表明绝大多数肝癌组织中存在着激活T细胞,为体内、外扩增这种具有杀伤活性的激活T细胞提供实验基础.其中No.14肝癌组织中可见大量TIL细胞侵润,绝大多数TIL细胞表达穿孔素及Fas-L,该例病人已1年6个月无复发,提示大量激活T细胞存在可能有利于肿瘤治疗,然而除该例病人外,其余病人的TIL的穿孔素及Fas-L阳性率<10%,表明仅有极少量TIL细胞处于免疫激活状态,具有杀
To study whether there are activated T cells in HCC and how to block the activation of T cells apoptosis and increase the lifespan of activated T cells is of great significance for the treatment of HCC. We applied immunohistochemistry and in situ hybridization to study tumor invasion in 20 HCC tissues. Perforin and Fas-L expression of lymphocytes (TIL) revealed that TIL cells expressing perforin and Fas-L exist in 80% of liver cancer tissues, indicating that activated T cells exist in most liver cancer tissues. This provides an experimental basis for the in vitro and in vivo expansion of such activated T cells with killer activity. Among them, a large number of TIL cells infiltrated in No. 14 hepatoma tissue. The vast majority of TIL cells expressed perforin and Fas-L. No recurrence has occurred for 1 year and 6 months, suggesting that the presence of a large number of activated T cells may be beneficial for tumor therapy. However, in addition to this patient, the perforin and Fas-L positive rate of TIL in other patients is <10%, indicating only a very small amount TIL cells are immune-activated and kill